scholarly journals Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy

2020 ◽  
Author(s):  
Serkan Yaman ◽  
Uday Chintapula ◽  
Edgar Rodriguez ◽  
Harish Ramachandramoorthy ◽  
Kytai T. Nguyen
2020 ◽  
Vol 8 (2) ◽  
pp. 552-568 ◽  
Author(s):  
Huaiji Wang ◽  
Ying Liu ◽  
Ruiqing He ◽  
Dailin Xu ◽  
Jie Zang ◽  
...  

Cell membrane coated nanoparticles have been designed for inflammation and cancer therapy. An array of cell membranes from cell library were extracted and leveraged to coat a variety of nanoparticles for different diseases.


2021 ◽  
Author(s):  
Mian Wang ◽  
Yuanfeng Xin ◽  
Hao Cao ◽  
Wanlu Li ◽  
Yifei Hua ◽  
...  

Studies of nanomedicine have achieved dramatic progress in recent decades.


2022 ◽  
Vol 11 ◽  
Author(s):  
Dan Mu ◽  
Pan He ◽  
Yesi Shi ◽  
Lai Jiang ◽  
Gang Liu

Immunotherapy can effectively activate the immune system and reshape the tumor immune microenvironment, which has been an alternative method in cancer therapy besides surgery, radiotherapy, and chemotherapy. However, the current clinical outcomes are not satisfied due to the lack of targeting of the treatment with some unexpected damages to the human body. Recently, cell membrane-based bioinspired nanoparticles for tumor immunotherapy have attracted much attention because of their superior immune regulating, drug delivery, excellent tumor targeting, and biocompatibility. Together, the article reviews the recent progress of cell membrane-based bioinspired nanoparticles for immunotherapy in cancer treatment. We also evaluate the prospect of bioinspired nanoparticles in immunotherapy for cancer. This strategy may open up new research directions for cancer therapy.


Author(s):  
Xuexia Tian ◽  
Anhua Shi ◽  
Junzi Wu

Backgroud: At present, the tumor is still the leading cause of death. Biomimetic nanocarriers for precision cancer therapy are attracting increasing attention. Nanocarriers with a good biocompatible surface could reduce the recognition and elimination of nanoparticles as foreign substances by the immune system, offer specific targeting, and improve the efficacy of precision medicine for tumors, thereby providing outstanding prospects for application in cancer therapy. In particular, cell membrane biomimetic camouflaged nanocarriers have become a research hotspot because of their excellent biocompatibility, prolonged circulation in the blood, and tumor targeting. Objective: To summarize the biological targeting mechanisms of different cell membrane-encapsulated nanocarriers in cancer therapy. In this article, the characteristics, application, and stage of progress of bionic encapsulated nanocarriers for different cell membranes are discussed, as are the field’s developmental prospects. Method: The findings on the characteristics of bionic encapsulated nanocarriers for different cell membranes and tumor treatment have been analyzed and summarized. Results: Biomimetic nanosystems based on various natural cell and hybrid cell membranes have been shown to efficiently control targeted drug delivery systems. They can reduce immune system clearance, prolong blood circulation time, and improve drug loading and targeting, thereby enhancing the diagnosis and treatment of tumors and reducing the spread of CTCs. Conclusion: :With advances in the development of biomimetic nanocarrier DDSs, novel ideas for tumor treatment and drug delivery have been developed. However, there are still some problems in biomimetic nanosystems. Therefore, it needs to be optimized through further research, from the laboratory to the clinic for the benefit of a wide range of patients.


2015 ◽  
Vol 3 (3) ◽  
pp. 490-499 ◽  
Author(s):  
Gongyan Liu ◽  
Quanqing Luo ◽  
Haiqi Gao ◽  
Yuan Chen ◽  
Xing Wei ◽  
...  

Cell membrane-inspired polymeric micelles were designed as drug carriers for cancer therapy.


2017 ◽  
Vol 60 (6) ◽  
pp. 504-510 ◽  
Author(s):  
Zhilan Chai ◽  
Xuefeng Hu ◽  
Weiyue Lu

Nano Letters ◽  
2014 ◽  
Vol 14 (4) ◽  
pp. 2181-2188 ◽  
Author(s):  
Ronnie H. Fang ◽  
Che-Ming J. Hu ◽  
Brian T. Luk ◽  
Weiwei Gao ◽  
Jonathan A. Copp ◽  
...  

2018 ◽  
Vol 5 (3) ◽  
pp. 175-187 ◽  
Author(s):  
O. V. Gorovtsova ◽  
T. L. Ushakova ◽  
V. G. Polyakov

Retinoblastoma is one of highly curable diseases; today the total 5-year survival rate in patients with retinoblastoma exceeds 95%. The article summarizes the current world experience on treatment of patients with intraocular retinoblastoma. The treating skills of intraocular malignant tumor in children are a balance between the patient’s life and the preservation of an eye and its visual functions. The complex and challenging task is the treatment of common intraocular retinoblastoma groups «C», «D», «E» when the large size or localization of the tumor does not allow performing the local (focal) destruction of the tumor. As a rule, in such cases neoadjuvant chemotherapy (CT) is performed at the first stage in order to reduce the size of the tumor for further focal therapy. However, the analysed data on the effectiveness of neoadjuvant CT in combination with focal or radiotherapy demonstrated the limited possibilities of the proposed therapy. Local drug delivery in cancer therapy became a real breakthrough in the organ-preserving treatment of children with large intraocular retinoblastoma. The most widely used current methods of local drug delivery are intravitreal (IVitC) and selective intra-arterial chemotherapy (SIAC) as monotherapy or in combination with neoadjuvant CT and focal therapy which significantly increased the percentage of preserved eyes without radiotherapy administration or damage to the patient survival. The review discusses the different IVitC and SIAC techniques, chemotherapy schemes, dosages of chemotherapy, immediate and long-term complications of treatment.


Sign in / Sign up

Export Citation Format

Share Document